Clinical trials
Completed Hematologic Neoplasms trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
37 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2006 | 2 |
| 2007 | 4 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 2 |
| 2016 | 3 |
| 2018 | 2 |
| 2021 | 4 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 37 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Azienda Ospedaliera San Giovanni Battista | 2 |
| Gamida Cell ltd | 2 |
| Gruppo Italiano Malattie EMatologiche dell'Adulto | 2 |
| Novartis Pharmaceuticals | 2 |
| Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne | 2 |
| A.O. Ospedale Papa Giovanni XXIII | 1 |
| AGC Biologics S.p.A. | 1 |
| Amgen | 1 |
| Armando Santoro, MD | 1 |
| AstraZeneca | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hematologic Neoplasms | 37 |
| Multiple Myeloma | 6 |
| Neoplasms | 6 |
| Myelodysplastic Syndromes | 5 |
| Leukemia, Myeloid, Acute | 4 |
| Lymphoma | 4 |
| Hodgkin Disease | 3 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 |
| Lymphoma, Large B-Cell, Diffuse | 3 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 |
Trials
Showing 1 to 25 of 37. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.